S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia

Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004)
Neuropsychopharmacology 29(5): 1004-1011.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ;
Abstract / Bemerkung
S100B, a calcium-binding protein produced by astroglial cells, mediates paracrine and autocrine effects on neurons and glial cells. It regulates the balance between proliferation and differentiation in neurons and glial cells by affecting protective and apoptotic mechanisms. Post-mortem studies have demonstrated a deficit in synapses and dendrites in brains of schizophrenics. Recent studies have shown increased S100B levels in medicated acutely psychotic schizophrenic patients as well as unmedicated or drug naive schizophrenics. One study reported a positive correlation between negative symptoms and S100B. S100B serum levels (quantitative immunoassay) and psychopathology (Positive and Negative Syndrome Scale, PANSS) were examined upon study admission and after 12 and 24 weeks of standardized treatment in 98 chronic schizophrenic patients with primarily negative symptoms. Compared to age- and sex-matched healthy controls, the schizophrenic patients showed significantly increased S100B concentrations upon admission and after 12 and 24 weeks of treatment. High PANSS negative scores were correlated with high S100B levels. Regression analysis comparing psychopathology subscales and S100B identified negative symptomatology as the predicting factor for S100B. S100B is not just elevated during acute stages of disease since it remains elevated for at least 6 months following an acute exacerbation. With regard to psychopathology, negative symptomatology appears to be the predicting factor for the absolute S100B concentration. This might indicate that S100B in schizophrenic patients either promotes apoptotic mechanisms by itself or is released from astrocytes as part of an attempt to repair a degenerative or destructive process.
Erscheinungsjahr
Zeitschriftentitel
Neuropsychopharmacology
Band
29
Ausgabe
5
Seite(n)
1004-1011
ISSN
PUB-ID

Zitieren

Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 2004;29(5):1004-1011.
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., & Arolt, V. (2004). S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology, 29(5), 1004-1011. doi:10.1038/sj.npp.1300403
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., and Arolt, V. (2004). S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29, 1004-1011.
Rothermundt, M., et al., 2004. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology, 29(5), p 1004-1011.
M. Rothermundt, et al., “S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia”, Neuropsychopharmacology, vol. 29, 2004, pp. 1004-1011.
Rothermundt, M., Ponath, G., Glaser, T., Hetzel, G., Arolt, V.: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology. 29, 1004-1011 (2004).
Rothermundt, M, Ponath, G, Glaser, Thorsten, Hetzel, G, and Arolt, V. “S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia”. Neuropsychopharmacology 29.5 (2004): 1004-1011.

52 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia.
Deng H, Kahlon RS, Mohite S, Amin PA, Zunta-Soares G, Colpo GD, Stertz L, Fries GR, Walss-Bass C, Soares JC, Okusaga OO., Psychiatr Q 89(1), 2018
PMID: 28435992
S100B polymorphisms are associated with age of onset of Parkinson's disease.
Fardell C, Zettergren A, Ran C, Carmine Belin A, Ekman A, Sydow O, Bäckman L, Holmberg B, Dizdar N, Söderkvist P, Nissbrandt H., BMC Med Genet 19(1), 2018
PMID: 29529989
Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia.
Morera-Fumero AL, Díaz-Mesa E, Abreu-Gonzalez P, Fernandez-Lopez L, Cejas-Mendez MDR., Prog Neuropsychopharmacol Biol Psychiatry 75(), 2017
PMID: 28188811
Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.
Xia M, Abazyan S, Jouroukhin Y, Pletnikov M., Schizophr Res 176(1), 2016
PMID: 25468180
Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia-A Meta-Regression Analysis.
Schümberg K, Polyakova M, Steiner J, Schroeter ML., Front Cell Neurosci 10(), 2016
PMID: 26941608
Evaluation of oxidant, antioxidant, and S100B levels in patients with conversion disorder.
Büyükaslan H, Kandemir SB, Asoğlu M, Kaya H, Gökdemir MT, Karababa İF, Güngörmez F, Kılıçaslan F, Şavik E., Neuropsychiatr Dis Treat 12(), 2016
PMID: 27471386
Glial cells as key players in schizophrenia pathology: recent insights and concepts of therapy.
Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B., Schizophr Res 161(1), 2015
PMID: 24948484
Glia-related genes and their contribution to schizophrenia.
Wang C, Aleksic B, Ozaki N., Psychiatry Clin Neurosci 69(8), 2015
PMID: 25759284
Reduced serum TNF alpha level in chronic schizophrenia patients with or without tardive dyskinesia.
Tian L, Tan Y, Chen D, Lv M, Tan S, Soares JC, Zhang XY., Prog Neuropsychopharmacol Biol Psychiatry 54(), 2014
PMID: 24995685
BDNF and S100B in psychotic disorders: evidence for an association with treatment responsiveness.
van de Kerkhof NW, Fekkes D, van der Heijden FM, Verhoeven WM., Acta Neuropsychiatr 26(4), 2014
PMID: 25142290
Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.
Aleksovska K, Leoncini E, Bonassi S, Cesario A, Boccia S, Frustaci A., PLoS One 9(9), 2014
PMID: 25202915
S100B and schizophrenia.
Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P., Psychiatry Clin Neurosci 67(2), 2013
PMID: 23438158
Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review.
Najjar S, Pearlman D, Devinsky O, Najjar A, Nadkarni S, Butler T, Zagzag D., Cogn Behav Neurol 26(1), 2013
PMID: 23538571
Levels of S100B are raised in female patients with schizophrenia.
O'Connell K, Thakore J, Dev KK., BMC Psychiatry 13(), 2013
PMID: 23705829
Chronic fluoxetine treatment changes S100B expression during postnatal rat brain development.
Bock N, Koc E, Alter H, Roessner V, Becker A, Rothenberger A, Manzke T., J Child Adolesc Psychopharmacol 23(7), 2013
PMID: 24024533
Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder.
van der Leeuw C, Marcelis M, Peeters SC, Verbeek MM, Menheere PP, de Haan L, van Os J, van Beveren NJ, Genetic Risk and Outcome in Psychosis (G.R.O.U.P.)., PLoS One 8(12), 2013
PMID: 24358202
The neuroimmunology of schizophrenia.
Smyth AM, Lawrie SM., Clin Psychopharmacol Neurosci 11(3), 2013
PMID: 24465246
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?
Vasic N, Connemann BJ, Wolf RC, Tumani H, Brettschneider J., Eur Arch Psychiatry Clin Neurosci 262(5), 2012
PMID: 22173848
The S100B protein in biological fluids: more than a lifelong biomarker of brain distress.
Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, Gazzolo D., J Neurochem 120(5), 2012
PMID: 22145907
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
Leonard BE, Schwarz M, Myint AM., J Psychopharmacol 26(5 suppl), 2012
PMID: 22472311
Effects of the putative antipsychotic alstonine on glutamate uptake in acute hippocampal slices.
Herrmann AP, Lunardi P, Pilz LK, Tramontina AC, Linck VM, Okunji CO, Gonçalves CA, Elisabetsky E., Neurochem Int 61(7), 2012
PMID: 22940693
Blood-brain barrier dysfunction in brain diseases: clinical experience.
Schoknecht K, Shalev H., Epilepsia 53 Suppl 6(), 2012
PMID: 23134490
Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia.
Zhai J, Zhang Q, Cheng L, Chen M, Wang K, Liu Y, Deng X, Chen X, Shen Q, Xu Z, Ji F, Liu C, Dong Q, Chen C, Li J., Behav Brain Res 217(2), 2011
PMID: 21070816
Functional assessment of a promoter polymorphism in S100B, a putative risk variant for bipolar disorder.
Dagdan E, Morris DW, Campbell M, Hill M, Rothermundt M, Kästner F, Hohoff C, von Eiff C, Krakowitzky P, Gill M, McKeon P, Roche S., Am J Med Genet B Neuropsychiatr Genet 156B(6), 2011
PMID: 21714070
Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders.
Kluge W, Alsaif M, Guest PC, Schwarz E, Bahn S., Expert Rev Mol Diagn 11(7), 2011
PMID: 21902534
Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
Zhang XY, Xiu MH, Chen DC, Zhu FY, Wu GY, Haile CN, Lu L, Kosten TA, Kosten TR., J Psychiatr Res 44(7), 2010
PMID: 19932492
Risk variants in the S100B gene predict elevated S100B serum concentrations in healthy individuals.
Hohoff C, Ponath G, Freitag CM, Kästner F, Krakowitzky P, Domschke K, Koelkebeck K, Kipp F, von Eiff C, Deckert J, Rothermundt M., Am J Med Genet B Neuropsychiatr Genet 153B(1), 2010
PMID: 19330775
Haloperidol and clozapine decrease S100B release from glial cells.
Steiner J, Schroeter ML, Schiltz K, Bernstein HG, Müller UJ, Richter-Landsberg C, Müller WE, Walter M, Gos T, Bogerts B, Keilhoff G., Neuroscience 167(4), 2010
PMID: 20226844
Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis.
Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE., Psychiatry Res 167(1-2), 2009
PMID: 19375171
Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics.
Qi LY, Xiu MH, Chen DC, Wang F, Kosten TA, Kosten TR, Zhang XY., Neurosci Lett 462(2), 2009
PMID: 19539717
Breaching the blood-brain barrier as a gate to psychiatric disorder.
Shalev H, Serlin Y, Friedman A., Cardiovasc Psychiatry Neurol 2009(), 2009
PMID: 19936105
S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study.
Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM, Bogerts B., J Psychiatr Res 42(10), 2008
PMID: 18001771
Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia.
Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, Ponath G, Kipp F, Abel S, Siegmund A, Suslow T, von Eiff C, Arolt V, Rothermundt M., Prog Neuropsychopharmacol Biol Psychiatry 32(8), 2008
PMID: 18718498
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin.
Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, Heinz G, Erdag S, Jahn H, Degner D, Ritzen M, Mohr A, Wagner M, Schneider U, Bohn M, Huber M, Czernik A, Pollmächer T, Maier W, Sirén AL, Klosterkötter J, Falkai P, Rüther E, Aldenhoff JB, Krampe H., Mol Psychiatry 12(2), 2007
PMID: 17033631
Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol.
Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B., Prog Neuropsychopharmacol Biol Psychiatry 31(2), 2007
PMID: 17081670
Increased serum S100B protein in chronic schizophrenic patients in Korea.
Ryoun Kim H, Kyung Lee M, Park DB., Clin Chem Lab Med 45(11), 2007
PMID: 17970711
Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites.
Nilsson-Todd LK, Nordin C, Jönsson EG, Skogh E, Erhardt S., Acta Neuropsychiatr 19(1), 2007
PMID: 26952797
Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment.
Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E., Prog Neuropsychopharmacol Biol Psychiatry 31(6), 2007
PMID: 17459548
Schizophrenia-associated neural growth factors in peripheral blood. A review.
van Beveren NJ, van der Spelt JJ, de Haan L, Fekkes D., Eur Neuropsychopharmacol 16(7), 2006
PMID: 16545550
The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.
Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, Rothermundt M., Psychopharmacology (Berl) 178(2-3), 2005
PMID: 15316717
S100B and NSE serum concentrations in Machado Joseph disease.
Tort AB, Portela LV, Rockenbach IC, Monte TL, Pereira ML, Souza DO, Rieder CR, Jardim LB., Clin Chim Acta 351(1-2), 2005
PMID: 15563883
Is there an immunologic basis for schizophrenia?
Leonard BE., Expert Rev Clin Immunol 1(1), 2005
PMID: 20477658
Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.
Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P., Schizophr Res 80(2-3), 2005
PMID: 15964742
Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.
Rothermundt M, Falkai P, Ponath G, Abel S, Bürkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V., Mol Psychiatry 9(10), 2004
PMID: 15241436

45 References

Daten bereitgestellt von Europe PubMed Central.


JL, Ann Biol Clin 57(), 1999
The S-100: a protein family in search of a function.
Fano G, Biocca S, Fulle S, Mariggio MA, Belia S, Calissano P., Prog. Neurobiol. 46(1), 1995
PMID: 7568910
Decreased S100-beta protein in schizophrenia: preliminary evidence.
Gattaz WF, Lara DR, Elkis H, Portela LV, Goncalves CA, Tort AB, Henna J, Souza DO., Schizophr. Res. 43(2-3), 2000
PMID: 10858627
T-maze spontaneous alternation rate is decreased in S100 beta transgenic mice.
Gerlai R, Marks A, Roder J., Behav. Neurosci. 108(1), 1994
PMID: 8192834
Senescence-accelerated overexpression of S100beta in brain of SAMP6 mice.
Griffin WS, Sheng JG, Mrak RE., Neurobiol. Aging 19(1), 1998
PMID: 9562506
A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures.
Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC., Arch. Gen. Psychiatry 55(2), 1998
PMID: 9477928

CW, Front Biosci 7(), 2002
Structural neuroimaging in schizophrenia. An integrative view of neuromorphology.
Henn FA, Braus DF., Eur Arch Psychiatry Clin Neurosci 249 Suppl 4(), 1999
PMID: 10654109
A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
Hirsch SR, Kissling W, Bauml J, Power A, O'Connor R., J Clin Psychiatry 63(6), 2002
PMID: 12088164
Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'.
Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS., Mol. Psychiatry 4(1), 1999
PMID: 10089007
The positive and negative syndrome scale (PANSS) for schizophrenia.
Kay SR, Fiszbein A, Opler LA., Schizophr Bull 13(2), 1987
PMID: 3616518
Synaptic changes in the striatum of schizophrenic cases: a controlled postmortem ultrastructural study.
Kung L, Conley R, Chute DJ, Smialek J, Roberts RC., Synapse 28(2), 1998
PMID: 9450513
Increased serum S100B protein in schizophrenia: a study in medication-free patients.
Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, Fonseca M, Hauck S, Souza DO., J Psychiatr Res 35(1), 2001
PMID: 11287051
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group., Am J Psychiatry 160(8), 2003
PMID: 12900300
Five-factor model of schizophrenia. Initial validation.
Lindenmayer JP, Bernstein-Hyman R, Grochowski S., J. Nerv. Ment. Dis. 182(11), 1994
PMID: 7964671
Schizophrenia as a disorder of developmentally reduced synaptic connectivity.
McGlashan TH, Hoffman RE., Arch. Gen. Psychiatry 57(7), 2000
PMID: 10891034
Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse.
Mirnics K, Middleton FA, Lewis DA, Levitt P., Trends Neurosci. 24(8), 2001
PMID: 11476888
Structural brain imaging in schizophrenia: a selective review.
Pearlson GD, Marsh L., Biol. Psychiatry 46(5), 1999
PMID: 10472416
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W., Psychiatry Res 88(2), 1999
PMID: 10622347
The neuropathology of schizophrenia.
Powers RE., J. Neuropathol. Exp. Neurol. 58(7), 1999
PMID: 10411337
Dynamics of brain-derived proteins in cerebrospinal fluid.
Reiber H., Clin. Chim. Acta 310(2), 2001
PMID: 11498083
Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology.
Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H., Mol. Psychiatry 6(4), 2001
PMID: 11443531
S100B in brain damage and neurodegeneration.
Rothermundt M, Peters M, Prehn JH, Arolt V., Microsc. Res. Tech. 60(6), 2003
PMID: 12645009
S100B in schizophrenic psychosis.
Rothermundt M, Ponath G, Arolt V., Int. Rev. Neurobiol. 59(), 2004
PMID: 15006498
Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.
Schroeter ML, Abdul-Khaliq H, Fruhauf S, Hohne R, Schick G, Diefenbacher A, Blasig IE., Schizophr. Res. 62(3), 2003
PMID: 12837519
The reduced neuropil hypothesis: a circuit based model of schizophrenia.
Selemon LD, Goldman-Rakic PS., Biol. Psychiatry 45(1), 1999
PMID: 9894571
A review of MRI findings in schizophrenia.
Shenton ME, Dickey CC, Frumin M, McCarley RW., Schizophr. Res. 49(1-2), 2001
PMID: 11343862
Association of neuregulin 1 with schizophrenia confirmed in a Scottish population.
Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, St Clair D., Am. J. Hum. Genet. 72(1), 2002
PMID: 12478479
Neuregulin 1 and susceptibility to schizophrenia.
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K., Am. J. Hum. Genet. 71(4), 2002
PMID: 12145742
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD., J Clin Psychopharmacol 17(5), 1997
PMID: 9315992
Elevated plasma levels of S-100b protein in schizophrenic patients.
Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, Kirchner H., Biol. Psychiatry 45(11), 1999
PMID: 10356634
Learning and memory in S100-beta transgenic mice: an analysis of impaired and preserved function.
Winocur G, Roder J, Lobaugh N., Neurobiol Learn Mem 75(2), 2001
PMID: 11222062

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 14997170
PubMed | Europe PMC

Suchen in

Google Scholar